News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
106,021 Results
Type
Article (3201)
Company Profile (54)
Press Release (102766)
Section
Business (33334)
Career Advice (201)
Deals (9887)
Drug Delivery (8)
Drug Development (10354)
Employer Resources (12)
FDA (1701)
Job Trends (2232)
News (55316)
Policy (3692)
Tag
Academia (218)
Alliances (8821)
Alzheimer's disease (153)
Approvals (1699)
Bankruptcy (90)
Best Places to Work (1788)
Biosimilars (15)
Biotechnology (39)
Breast cancer (15)
Cancer (160)
Career advice (171)
Cell therapy (26)
Clinical research (8192)
Collaboration (58)
Compensation (28)
COVID-19 (244)
C-suite (21)
Data (130)
Diagnostics (1061)
Earnings (10746)
Events (15175)
Executive appointments (69)
FDA (1764)
Funding (73)
Gene therapy (12)
GLP-1 (67)
Government (318)
Healthcare (2601)
Infectious disease (249)
Inflammatory bowel disease (18)
Interviews (29)
IPO (5434)
Job creations (476)
Job search strategy (152)
Layoffs (38)
Legal (1075)
Lung cancer (28)
Manufacturing (15)
Medical device (2042)
Medtech (2042)
Mergers & acquisitions (4529)
Metabolic disorders (30)
Neuroscience (198)
NextGen Class of 2024 (1200)
Non-profit (305)
Northern California (305)
Obesity (14)
Opinion (15)
Patents (22)
People (11130)
Phase I (2878)
Phase II (3914)
Phase III (2518)
Pipeline (47)
Postmarket research (175)
Preclinical (1166)
Radiopharmaceuticals (51)
Rare diseases (24)
Real estate (901)
Regulatory (2456)
Research institute (273)
Resumes & cover letters (23)
Schizophrenia (13)
Southern California (304)
Startups (917)
United States (2426)
Vaccines (31)
Date
Today (37)
Last 7 days (150)
Last 30 days (597)
Last 365 days (6923)
2024 (5937)
2023 (7982)
2022 (9887)
2021 (11209)
2020 (10432)
2019 (7051)
2018 (5427)
2017 (5471)
2016 (4643)
2015 (6094)
2014 (4291)
2013 (3544)
2012 (3897)
2011 (3556)
2010 (3167)
Location
Africa (61)
Arizona (30)
Asia (5301)
Australia (703)
California (721)
Canada (154)
China (22)
Colorado (18)
Connecticut (26)
Europe (8503)
Florida (85)
Georgia (16)
Illinois (46)
Indiana (49)
Kansas (27)
Maine (28)
Maryland (77)
Massachusetts (354)
Michigan (47)
Minnesota (30)
Nevada (20)
New Jersey (146)
New York (189)
North Carolina (195)
Northern California (305)
Ohio (40)
Pennsylvania (117)
South America (99)
Southern California (304)
Texas (93)
Utah (23)
Virginia (14)
Washington State (44)
106,021 Results for "kashiv biosciences llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into an exclusive licensing agreement for ADL018 with Amneal Pharmaceuticals, Inc.
July 1, 2024
·
7 min read
Press Releases
Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO
November 4, 2024
·
2 min read
Drug Development
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR® (omalizumab)
Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has enrolled the first patient in its Phase III clinical study involving ADL018, the Company’s biosimilar candidate to XOLAIR®.
October 2, 2023
·
3 min read
Pharm Country
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Alvotech and Kashiv Biosciences LLC announced that they have entered into an exclusive licensing agreement for AVT23, a proposed biosimilar to Xolair®, which is currently in clinical development.
October 3, 2023
·
8 min read
Business
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Kashiv Biosciences LLC today announced that they have entered into an exclusive licensing agreement for ADL018 (also called AVT23), a proposed biosimilar to Xolair® (omalizumab), which is in clinical development.
October 3, 2023
·
9 min read
Drug Development
Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair® (omalizumab)
Kashiv Biosciences, LLC announced that ADL018, a biosimilar candidate to Xolair®, completed a successful global Phase 1 clinical study in healthy volunteers.
July 5, 2023
·
3 min read
Press Releases
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
October 24, 2024
·
1 min read
Deals
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC.
November 27, 2023
·
4 min read
FDA
Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)
Kashiv Biosciences, LLC (“Kashiv” or the “Company”) is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved its Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®.
May 31, 2022
·
4 min read
FDA
Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)
Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®.
March 2, 2022
·
4 min read
1 of 10,603
Next